---
title: "N-acetyl Cysteine: the Effectiveness and Safety in a Cohort of Pediatric Patients With Chronic Kidney Disease"
nct_id: NCT04916080
overall_status: COMPLETED
phase: PHASE2
sponsor: Beni-Suef University
study_type: INTERVENTIONAL
primary_condition: Chronic Kidney Diseases
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04916080.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04916080"
ct_last_update_post_date: 2023-04-11
last_seen_at: "2026-05-12T06:58:55.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# N-acetyl Cysteine: the Effectiveness and Safety in a Cohort of Pediatric Patients With Chronic Kidney Disease

**NCT ID:** [NCT04916080](https://clinicaltrials.gov/study/NCT04916080)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Beni-Suef University
- **Collaborators:** Cairo University
- **Conditions:** Chronic Kidney Diseases
- **Start Date:** 2021-11-01
- **Completion Date:** 2023-01-01
- **CT.gov Last Update:** 2023-04-11

## Brief Summary

Anemia is a common comorbidity of CKD and is associated with a decreased quality of life and increased healthcare resource utilization. Anemia increases the risk of CKD progression, cardiovascular complications, and overall mortality. The current standard of care includes oral or intravenous iron supplementation, erythropoiesis-stimulating agents, and red blood cell transfusion. Treatment with high doses of erythropoiesis-stimulating agents increases rates of hospitalization, cardiovascular events, and mortality. Resistance to erythropoiesis-stimulating agents is a therapeutic challenge in many patients .

NAC reduces the risk of progression of CKD of any etiology to end stage renal disease (ESRD) but the mechanism by which it reduces the progression of CKD to ESRD is unclear. It may be because of its antioxidant and vasodilatory nature. Prolonged duration of administration and higher dosage of NAC can protect kidneys.

## Detailed Description

All patients with chronic kidney disease on regular hemodialysis will be enrolled.

\- Study location: The patients will be recruited from pediatric nephrology department, Cairo University Children's Hospital and Beni Suef University.

History taking including the age, sex, primary cause of CKD, onset of hemodialysis, medications including erythropoietin dose, frequency, and duration, oral or intravenous iron therapy, and frequency of blood transfusion.

Clinical examination focusing on pallor, blood pressure, and anthropometric measurements and their percentile.

Investigations including hemoglobin level at the start of the study and every month during the study period, serum ferritin, alanine aminotransferase, total oxidative stress (TOS), total antioxidant capacity (TAC), and oxidative stress index (OSI) at the start and after 3 months of the onset of the study.

Patients will receive N-acetyl cysteine (10 mg/kg/day, orally). The duration of the study will 3 months.

## Eligibility

- **Minimum age:** 6 Months
- **Maximum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* pediatric patients with chronic kidney diseases stage 3, 4 or 5

Exclusion Criteria:

* Unwilling to participate in the study.
* non-compliant patients on the standard care of CKD.

  * Patients with cardiac, endocrinal, and hepatic complications.
  * Asthma or known allergy to NAC.
  * Any chronic infections prior to or during the study period.
```

## Arms

- **after treatment** (EXPERIMENTAL) — chronic kidney disease patients after receiving NAC for 3 months

## Interventions

- **N-acetyl cysteine** (DRUG) — mucolytic and anti-oxidant. Dose 10mg/Kg/ 12 hours orally

## Primary Outcomes

- **hemoglobin (gm%)** _(time frame: 3 months)_ — the change in levels of hemoglobin after treatment
- **oxidative status** _(time frame: 3 months)_ — rate of change of total oxidative status after treatment using ELISA kits
- **left ventricular function** _(time frame: 3 months)_ — rate of change of left ventricular functions before and after treatment by electrocardiography
- **serum Ferritin level (mg/dl)** _(time frame: 3 months)_ — the change in levels of d ferritin after treatment using specific kits
- **Anti-oxidative status** _(time frame: 3 months)_ — rate of change of anti oxidant capacity after treatment

## Secondary Outcomes

- **serious side effects** _(time frame: 3 months)_

## Locations (2)

- Beni-Suef university hospital, Banī Suwayf, Egypt
- Pediatric nephrology and transplantation unite.Aboelrish children hospital, Cairo, Egypt

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.beni-suef university hospital|banī suwayf||egypt` — added _(2026-05-12)_
- `locations.pediatric nephrology and transplantation unite.aboelrish children hospital|cairo||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04916080.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04916080*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*